{"id":"fludarabine-flu","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"30-50","effect":"Infection"},{"rate":"20-40","effect":"Nausea and vomiting"},{"rate":"15-25","effect":"Fever"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-15","effect":"Neurotoxicity (confusion, peripheral neuropathy)"},{"rate":"5-10","effect":"Tumor lysis syndrome"}]},"_chembl":{"chemblId":"CHEMBL1096882","moleculeType":"Small molecule","molecularWeight":"365.21"},"_dailymed":{"setId":"cf5255cc-91fd-4132-973b-764dba142eae","title":"FLUDARABINE (FLUDARABINE PHOSPHATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fludarabine is a fluorinated purine nucleoside analog that is phosphorylated intracellularly to its active form, fludarabine triphosphate. This active metabolite inhibits both ribonucleotide reductase and DNA polymerase, disrupting DNA synthesis and repair. The resulting DNA damage triggers apoptosis, particularly in lymphoid malignancies where cells have high proliferation rates and limited DNA repair capacity.","oneSentence":"Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to DNA strand breaks and apoptosis in rapidly dividing cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:54:50.272Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Follicular lymphoma"},{"name":"Small lymphocytic lymphoma (SLL)"}]},"trialDetails":[{"nctId":"NCT04990323","phase":"PHASE1, PHASE2","title":"US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies","status":"COMPLETED","sponsor":"ExCellThera inc.","startDate":"2021-12-01","conditions":"High Risk Myeloid Malignancies, Cord Blood Transplant","enrollment":13},{"nctId":"NCT02287311","phase":"PHASE1","title":"Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2015-02","conditions":"Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus","enrollment":38},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT07480928","phase":"PHASE1, PHASE2","title":"Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease","enrollment":42},{"nctId":"NCT07396480","phase":"PHASE3","title":"Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-03-01","conditions":"Venentoclax, Myeloid Malignancies, Conditioning","enrollment":186},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT04347616","phase":"PHASE1, PHASE2","title":"Natural Killer-cell Therapy for Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2020-12-03","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult","enrollment":9},{"nctId":"NCT01804634","phase":"PHASE2","title":"Reduced Intensity Haploidentical BMT for High Risk Solid Tumors","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-03-27","conditions":"Refractory and/or Relapsed Metastatic Solid Tumors","enrollment":60},{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT01962636","phase":"NA","title":"Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-12","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia","enrollment":200},{"nctId":"NCT03070327","phase":"PHASE1","title":"BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-02-27","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT06121297","phase":"PHASE1, PHASE2","title":"RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Cabaletta Bio","startDate":"2024-02-16","conditions":"Systemic Lupus Erythematosus, Lupus Nephritis","enrollment":28},{"nctId":"NCT07410676","phase":"PHASE1, PHASE2","title":"EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Essen Biotech","startDate":"2026-02-01","conditions":"Cancer, Sarcoma, Leukaemia","enrollment":83},{"nctId":"NCT06152172","phase":"PHASE1","title":"CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Porter","startDate":"2024-08-05","conditions":"Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis","enrollment":24},{"nctId":"NCT06325748","phase":"PHASE1","title":"SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Senti Biosciences","startDate":"2024-04-22","conditions":"AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies","enrollment":21},{"nctId":"NCT04067414","phase":"PHASE1","title":"Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2018-06-08","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma","enrollment":12},{"nctId":"NCT03579875","phase":"PHASE2","title":"Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-11-13","conditions":"Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes","enrollment":48},{"nctId":"NCT02065362","phase":"PHASE1","title":"TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2015-02","conditions":"EBV-positive Nasopharyngeal Carcinoma","enrollment":14},{"nctId":"NCT03159702","phase":"PHASE2","title":"Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-12-08","conditions":"Hematological Malignancy, Multiple Myeloma","enrollment":43},{"nctId":"NCT06451159","phase":"PHASE1","title":"A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bruce Cree","startDate":"2024-06-20","conditions":"Progressive Multiple Sclerosis","enrollment":10},{"nctId":"NCT06946225","phase":"PHASE1","title":"ACTengine® IMA203 Combined With mRNA-4203","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-07-25","conditions":"Cutaneous Melanoma, Synovial Sarcoma","enrollment":15},{"nctId":"NCT07324889","phase":"PHASE1, PHASE2","title":"An Open-label, Single-arm, Prospective, Multicenter, Phase I/II Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Yihao Wang","startDate":"2026-01-31","conditions":"Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia","enrollment":24},{"nctId":"NCT03674411","phase":"PHASE2","title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2019-01-02","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia","enrollment":22},{"nctId":"NCT07153068","phase":"PHASE1, PHASE2","title":"SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-06-28","conditions":"T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML)","enrollment":12},{"nctId":"NCT04191187","phase":"PHASE2","title":"Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-12-06","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia","enrollment":34},{"nctId":"NCT07100873","phase":"PHASE1","title":"A Phase 1 Study of ADI-001 in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Adicet Therapeutics","startDate":"2025-10-10","conditions":"Rheumatoid Arthritis (RA)","enrollment":25},{"nctId":"NCT04864054","phase":"PHASE1, PHASE2","title":"T-Cell Therapy (ECT204) in Adults With Advanced HCC","status":"RECRUITING","sponsor":"Eureka Therapeutics Inc.","startDate":"2022-03-11","conditions":"Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Neoplasm","enrollment":20},{"nctId":"NCT06080191","phase":"PHASE1","title":"Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL","status":"RECRUITING","sponsor":"Bambino Gesù Hospital and Research Institute","startDate":"2024-04-28","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":24},{"nctId":"NCT07259070","phase":"PHASE1, PHASE2","title":"Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-11-29","conditions":"DLBCL, CLL, FL","enrollment":20},{"nctId":"NCT07259161","phase":"PHASE2","title":"Modified Conditioning Regimen for CML-BP","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-15","conditions":"CML,Blast Phase, HSCT","enrollment":40},{"nctId":"NCT07225439","phase":"PHASE1","title":"Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","status":"NOT_YET_RECRUITING","sponsor":"Paolo Caimi, MD","startDate":"2025-12","conditions":"Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":15},{"nctId":"NCT02828592","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia","status":"RECRUITING","sponsor":"Northside Hospital, Inc.","startDate":"2016-09-09","conditions":"Severe Aplastic Anemia","enrollment":20},{"nctId":"NCT03396575","phase":"PHASE1","title":"Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-07-17","conditions":"Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma","enrollment":11},{"nctId":"NCT00881920","phase":"PHASE1","title":"Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2009-07","conditions":"Lymphoma, Myeloma, Leukemia","enrollment":54},{"nctId":"NCT03016806","phase":"","title":"Umbilical Cord Blood Transplantation From Unrelated Donors","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2015-06","conditions":"Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder","enrollment":30},{"nctId":"NCT07168486","phase":"PHASE1","title":"CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas","status":"ENROLLING_BY_INVITATION","sponsor":"University of Maryland, Baltimore","startDate":"2024-10-28","conditions":"B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)","enrollment":15},{"nctId":"NCT05884333","phase":"PHASE2","title":"Cord Blood Transplant in Adults With Blood Cancers","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-05-22","conditions":"Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML)","enrollment":54},{"nctId":"NCT07109518","phase":"PHASE1","title":"uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-06-28","conditions":"Acute Myeloid Leukemia (AML), T Lymphoblastic Leukemia/Lymphoma","enrollment":12},{"nctId":"NCT07131085","phase":"PHASE1","title":"QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS)","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2025-08-15","conditions":"MDS, AML","enrollment":9},{"nctId":"NCT07120607","phase":"PHASE1","title":"Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2025-08-18","conditions":"Leukemia","enrollment":9},{"nctId":"NCT02793544","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide","status":"COMPLETED","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2016-12","conditions":"Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma","enrollment":80},{"nctId":"NCT07106749","phase":"PHASE1","title":"CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-06-28","conditions":"Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma","enrollment":12},{"nctId":"NCT03575351","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-10-23","conditions":"Lymphoma, Non-Hodgkin","enrollment":184},{"nctId":"NCT02917083","phase":"PHASE1","title":"CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2017-05-08","conditions":"Hodgkin's Lymphoma, Non-Hodgkin Lymphoma","enrollment":60},{"nctId":"NCT05735717","phase":"PHASE2","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-11","conditions":"Hematologic Malignancy, Acute Leukemia, Remission","enrollment":70},{"nctId":"NCT07078721","phase":"PHASE2","title":"Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-07-20","conditions":"Aplastic Anemia Idiopathic","enrollment":11},{"nctId":"NCT07052422","phase":"PHASE2, PHASE3","title":"VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-07-15","conditions":"Older Patients, Myeloid Malignancies, Conditioning","enrollment":160},{"nctId":"NCT04558736","phase":"PHASE2","title":"Haploidentical HCT for Severe Aplastic Anemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-01-21","conditions":"Aplastic Anemia, Bone Marrow Failure Syndrome","enrollment":21},{"nctId":"NCT05805605","phase":"PHASE2","title":"Allo HSCT Using RIC and PTCy for Hematological Diseases","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-01","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia","enrollment":56},{"nctId":"NCT06802315","phase":"PHASE2","title":"Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-02-04","conditions":"Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory, Chronic Myeloid Leukemia - Accelerated Phase","enrollment":38},{"nctId":"NCT06680661","phase":"PHASE2","title":"ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis","status":"RECRUITING","sponsor":"Leland Metheny","startDate":"2025-02-25","conditions":"Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia","enrollment":20},{"nctId":"NCT02988466","phase":"PHASE2","title":"Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-01-24","conditions":"Hematologic Malignancies","enrollment":78},{"nctId":"NCT06674382","phase":"NA","title":"Haplo-HSCT for Myelofibrosis","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-01-01","conditions":"Myelofibrosis","enrollment":39},{"nctId":"NCT06125483","phase":"NA","title":"TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-11-01","conditions":"Hematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell Transplantation","enrollment":38},{"nctId":"NCT01163357","phase":"PHASE1","title":"Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2011-01-28","conditions":"Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia","enrollment":18},{"nctId":"NCT04547049","phase":"PHASE3","title":"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-09-01","conditions":"Leukemia","enrollment":176},{"nctId":"NCT05991908","phase":"PHASE3","title":"Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-10-19","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":222},{"nctId":"NCT06773091","phase":"PHASE1","title":"A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai NK Cell Technology Co., LTD","startDate":"2025-02-07","conditions":"Advanced Solid Tumors","enrollment":76},{"nctId":"NCT06809699","phase":"PHASE1","title":"Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"He Huang","startDate":"2022-08-04","conditions":"Hematologic Diseases","enrollment":29},{"nctId":"NCT06809712","phase":"PHASE1","title":"Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"He Huang","startDate":"2022-08-04","conditions":"Hematologic Disease","enrollment":29},{"nctId":"NCT05885464","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beam Therapeutics Inc.","startDate":"2023-05-25","conditions":"Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia","enrollment":5},{"nctId":"NCT06613035","phase":"PHASE3","title":"Twice-per-weekSelinexor, 2 Days Melphalan","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-09-30","conditions":"Acute Myeloid Leukemia","enrollment":126},{"nctId":"NCT06602323","phase":"PHASE2","title":"TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.","status":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2024-10-01","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT06571825","phase":"PHASE4","title":"RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR","status":"RECRUITING","sponsor":"He Huang","startDate":"2024-07-17","conditions":"Acute Myeloid Leukemia","enrollment":118},{"nctId":"NCT03743246","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"TERMINATED","sponsor":"Celgene","startDate":"2018-10-17","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin","enrollment":21},{"nctId":"NCT04009525","phase":"PHASE4","title":"Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study","status":"COMPLETED","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2019-07-05","conditions":"Thalassemia Major","enrollment":823},{"nctId":"NCT06468267","phase":"PHASE2","title":"RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.","status":"RECRUITING","sponsor":"Xianmin Song, MD","startDate":"2024-07-15","conditions":"Peripheral T Cell Lymphoma","enrollment":50},{"nctId":"NCT06111612","phase":"","title":"Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-01-20","conditions":"Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia","enrollment":50},{"nctId":"NCT03367546","phase":"PHASE2","title":"Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-07-02","conditions":"Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders","enrollment":5},{"nctId":"NCT06297772","phase":"PHASE3","title":"Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-06-01","conditions":"AML, Adult","enrollment":220},{"nctId":"NCT06247917","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2024-03-03","conditions":"Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Myelodysplastic Syndromes","enrollment":59},{"nctId":"NCT05613348","phase":"PHASE1, PHASE2","title":"CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma","status":"WITHDRAWN","sponsor":"Zhujiang Hospital","startDate":"2022-12-01","conditions":"B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Unspecified","enrollment":""},{"nctId":"NCT01949129","phase":"PHASE2, PHASE3","title":"Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2013-04","conditions":"Acute Lymphoblastic Leukaemia","enrollment":1800},{"nctId":"NCT06155188","phase":"NA","title":"Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2019-09-29","conditions":"Leukemia, Stem Cell Transplant, Cord Blood","enrollment":60},{"nctId":"NCT04989335","phase":"PHASE2","title":"Bisantrene Combination for Resistant AML","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2021-08-02","conditions":"Myelogenous Leukemia, Acute","enrollment":29},{"nctId":"NCT04269811","phase":"PHASE2","title":"Flu-Bu-Mel Conditioning Regimen for Myeloid Disease","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-01-15","conditions":"Relapse Rate After Allo-HSCT","enrollment":49},{"nctId":"NCT04897139","phase":"PHASE2","title":"Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-01-01","conditions":"Lymphoid Neoplasm","enrollment":23},{"nctId":"NCT05395052","phase":"PHASE1","title":"FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors","status":"TERMINATED","sponsor":"Fate Therapeutics","startDate":"2022-05-31","conditions":"Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer","enrollment":5},{"nctId":"NCT05069935","phase":"PHASE1","title":"FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors","status":"TERMINATED","sponsor":"Fate Therapeutics","startDate":"2021-10-15","conditions":"Solid Tumor, Adult","enrollment":16},{"nctId":"NCT03882203","phase":"PHASE2","title":"CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2018-08-01","conditions":"Refractory Hematologic Cancer, Allogeneic Stem Cell Transplantation","enrollment":18},{"nctId":"NCT03050216","phase":"PHASE2","title":"QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-05-16","conditions":"Acute Myeloid Leukemia","enrollment":8},{"nctId":"NCT05929092","phase":"NA","title":"TFBC Combined With UCBT in the Treatment of High-risk Malignant Hematological Diseases","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-06-01","conditions":"Hematopoietic Stem Cell Transplantation, Malignant Hematological Diseases","enrollment":40},{"nctId":"NCT04067180","phase":"NA","title":"Randomized Clinical Study Assessing Haplo vs. URD in AML","status":"TERMINATED","sponsor":"Karolinska Institutet","startDate":"2019-11-12","conditions":"Acute Myeloid Leukemia","enrollment":18},{"nctId":"NCT05453552","phase":"PHASE2, PHASE3","title":"G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2022-07-01","conditions":"Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning","enrollment":242},{"nctId":"NCT04323657","phase":"PHASE1, PHASE2","title":"TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"TCR2 Therapeutics","startDate":"2020-03-27","conditions":"Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma","enrollment":6},{"nctId":"NCT05739630","phase":"PHASE2, PHASE3","title":"M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-01-01","conditions":"Acute Leukemia","enrollment":60},{"nctId":"NCT05727683","phase":"PHASE1","title":"CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","startDate":"2022-04-28","conditions":"Acute Lymphocytic Leukemia","enrollment":33},{"nctId":"NCT05322330","phase":"PHASE2","title":"Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-02-10","conditions":"Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","enrollment":20},{"nctId":"NCT00589316","phase":"PHASE1","title":"Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2007-10-05","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":26},{"nctId":"NCT01339910","phase":"PHASE3","title":"Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2011-06","conditions":"Leukemia, Myelocytic, Acute","enrollment":272},{"nctId":"NCT01410344","phase":"PHASE2","title":"Allogeneic Transplant in HIV Patients (BMT CTN 0903)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2011-09","conditions":"Leukemia, Lymphoma, HIV","enrollment":20},{"nctId":"NCT02556931","phase":"PHASE2","title":"Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-12","conditions":"Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":117},{"nctId":"NCT03852407","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning","status":"RECRUITING","sponsor":"University of Liege","startDate":"2019-02-04","conditions":"Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia in Remission","enrollment":114},{"nctId":"NCT05290662","phase":"","title":"Registry of Patients Having Received oNKord®","status":"RECRUITING","sponsor":"Glycostem Therapeutics BV","startDate":"2022-06-14","conditions":"AML","enrollment":50},{"nctId":"NCT05472610","phase":"PHASE2","title":"Study of Efficacy of BZ019 in Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"Shanghai Mengchao Cancer Hospital","startDate":"2021-06-04","conditions":"Large B-cell Lymphoma","enrollment":36},{"nctId":"NCT02833805","phase":"PHASE2","title":"NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-09","conditions":"Severe Aplastic Anemia, Aplastic Anemia, Bone Marrow Failure","enrollment":21},{"nctId":"NCT05449899","phase":"PHASE2, PHASE3","title":"G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2022-07","conditions":"Secondary Acute Myeloid Leukemia Evolving From MDS, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning","enrollment":232},{"nctId":"NCT05303727","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-08","conditions":"Neuroblastoma","enrollment":64},{"nctId":"NCT04632316","phase":"PHASE1, PHASE2","title":"A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Glycostem Therapeutics BV","startDate":"2020-12-08","conditions":"Acute Myeloid Leukemia","enrollment":33},{"nctId":"NCT01471444","phase":"PHASE3","title":"Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-11-02","conditions":"Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection","enrollment":256}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"}],"_approvalHistory":[],"publicationCount":293,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FLU","FaraA"],"phase":"marketed","status":"active","brandName":"Fludarabine (FLU)","genericName":"Fludarabine (FLU)","companyName":"Nanfang Hospital, Southern Medical University","companyId":"nanfang-hospital-southern-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to DNA strand breaks and apoptosis in rapidly dividing cells. Used for Chronic lymphocytic leukemia (CLL), Follicular lymphoma, Small lymphocytic lymphoma (SLL).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}